Literature DB >> 24654989

Proteomics of osteosarcoma.

Giulia Bernardini1, Marcella Laschi, Michela Geminiani, Annalisa Santucci.   

Abstract

Osteosarcoma (OS) is the most common primary malignant tumor of bone and the third most common cancer in childhood and adolescence. Nowadays, early diagnosis, drug resistance and recurrence of the disease represent the major challenges in OS treatment. Post-genomics, and in particular proteomic technologies, offer an invaluable opportunity to address the level of biological complexity expressed by OS. Although the main goal of OS oncoproteomics is focused on diagnostic and prognostic biomarker discovery, in this review we describe and discuss global protein profiling approaches to other aspects of OS biology and pathophysiology, or to investigate the mechanism of action of chemotherapeutics. In addition, we present proteomic analyses carried out on OS cell lines as in vitro models for studying osteoblastic cell biology and the attractive opportunity offered by proteomics of OS cancer stem cells.

Entities:  

Keywords:  cell model; osteosarcoma; osteosarcoma pathophysiology; osteosarcoma therapy; post-genomics; proteomics

Mesh:

Substances:

Year:  2014        PMID: 24654989     DOI: 10.1586/14789450.2014.900445

Source DB:  PubMed          Journal:  Expert Rev Proteomics        ISSN: 1478-9450            Impact factor:   3.940


  8 in total

Review 1.  Molecular genetics of osteosarcoma.

Authors:  Kirby Rickel; Fang Fang; Jianning Tao
Journal:  Bone       Date:  2016-10-17       Impact factor: 4.398

2.  Differential expression of AURKA/PLK4 in quiescence and senescence of osteosarcoma U2OS cells.

Authors:  Xiao-Liang Xie; Hai-Xia Zhu; Yu-Mei Li; De-Ta Chen; Tian-You Fan
Journal:  Cell Cycle       Date:  2020-03-21       Impact factor: 4.534

3.  Clinical significance of serum soluble B7-H3 in patients with osteosarcoma.

Authors:  Ling Wang; Fu-Biao Kang; Guo-Chuan Zhang; Juan Wang; Ming-Fang Xie; Ying-Ze Zhang
Journal:  Cancer Cell Int       Date:  2018-08-13       Impact factor: 5.722

4.  Screening of disorders associated with osteosarcoma by integrated network analysis.

Authors:  Yongfeng Dou; Kai Zhu; Zhaozhong Sun; Xiaopeng Geng; Qingmin Fang
Journal:  Biosci Rep       Date:  2019-05-21       Impact factor: 3.840

Review 5.  A Review of T-Cell Related Therapy for Osteosarcoma.

Authors:  Kazushige Yoshida; Masanori Okamoto; Kaoru Aoki; Jun Takahashi; Naoto Saito
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

6.  Single-Cell Profiling of Tumor Microenvironment Heterogeneity in Osteosarcoma Identifies a Highly Invasive Subcluster for Predicting Prognosis.

Authors:  Junfeng Guo; Hong Tang; Pan Huang; Junfeng Guo; Youxing Shi; Chengsong Yuan; Taotao Liang; Kanglai Tang
Journal:  Front Oncol       Date:  2022-04-06       Impact factor: 5.738

7.  CNOT1 cooperates with LMNA to aggravate osteosarcoma tumorigenesis through the Hedgehog signaling pathway.

Authors:  Dong-Dong Cheng; Jing Li; Shi-Jie Li; Qing-Cheng Yang; Cun-Yi Fan
Journal:  Mol Oncol       Date:  2017-03-06       Impact factor: 6.603

8.  Delineation of hypoxia-induced proteome shifts in osteosarcoma cells with different metastatic propensities.

Authors:  Zifeng Song; Martin C Pearce; Yuan Jiang; Liping Yang; Cheri Goodall; Cristobal L Miranda; Milan Milovancev; Shay Bracha; Siva K Kolluri; Claudia S Maier
Journal:  Sci Rep       Date:  2020-01-20       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.